BOSTON, Mass. — September 19, 2025 – Averna Therapeutics, Inc., a biotechnology company developing novel genomic medicines based on gene insertion technology, today announced its selection as an Endpoints 11 winner for 2025. Endpoints 11 is an annual list of the 11 most promising biotech companies, curated by the Endpoints News editorial team.

“We are honored to be recognized as an Endpoints 11 company and proud to stand among an inspiring group of innovators driving key advancements in medicine,” said Tom Barnes, Averna Therapeutics CEO and Board Member. “The award reflects the potential of our vision to safely expand the reach of genomic medicines, while greatly simplifying the means to do so.”

The 2025 Endpoints 11 winners were announced at an awards gala held in Boston on Thursday, September 18, 2025.

Averna Therapeutics is creating the last, great missing tool required to break through the most persistent barriers in genomic medicine. Gene insertion technologies have the potential to treat diseases by introducing critical new or missing instructions to cells; however, current genetic medicine tools have struggled to safely and effectively deliver and durably integrate large sets of instructions. Averna’s all-RNA approach overcomes these challenges by improving upon the innate properties of a naturally occurring class of site-specific retrotransposons to precisely integrate entire genes into a safe harbor location within the genome.

Averna is a biotechnology company developing genomic medicines designed to insert any gene or genetic instruction of interest safely and efficiently into “safe harbor” sites in the genome. Our platform configures a modular, all-RNA system combined with multiple LNP delivery solutions. This proprietary approach has the potential to expand the reach of genomic medicines, increasing the scope of addressable diseases including cancer, autoimmune and rare genetic diseases – broadening the patient populations able to benefit from this potentially life-changing class of therapies. For more information, please visit www.avernatx.com.

Media Contact:

Peg Rusconi

Deerfield Group

peg.rusconi@deerfieldgroup.com